Press Releases

Press Releases

    Date Title View
    01/13/20
    Summary ToggleHorizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs
    PDF Version
    01/13/20
    Summary ToggleMIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
    PDF Version
    12/13/19
    Summary ToggleFDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)
    PDF Version
    12/13/19
    Summary ToggleHorizon Therapeutics plc Trading Halted Today; FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting to Discuss Teprotumumab for Thyroid Eye Disease
    PDF Version
    12/09/19
    Summary ToggleHorizon Therapeutics plc to Present at the 38th Annual J.P. Morgan Healthcare Conference
    PDF Version
    11/22/19
    Summary ToggleHorizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco
    PDF Version
    11/21/19
    Summary ToggleHorizon Therapeutics plc Launches New Online Community Connecting People Living with Thyroid Eye Disease and Urging them to “Listen to Your Eyes”
    PDF Version
    11/14/19
    Summary ToggleFORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List
    PDF Version
    11/13/19
    Summary ToggleHorizon Therapeutics plc to Participate in Upcoming Investor Conferences
    PDF Version
    11/11/19
    Summary ToggleData from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes
    PDF Version
    Displaying 1 - 10 of 480 results